| Schedule of significant segment expenses |
The following table sets forth the significant segment expenses for our one reportable segment (in thousands): | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Operating expenses | | | | | | | | | | | | | Research and development | | | | | | | | | | | | | Direct costs | | | | | | | | | | | | | Vanoglipel | | $ | 235 | | $ | 277 | | $ | 402 | | $ | 568 | DA-1726 | | | 2,717 | | | 1,529 | | | 4,164 | | | 3,008 | Other R&D (1) | | | 40 | | | 30 | | | 53 | | | 55 | Indirect costs | | | | | | | | | | | | | Employee compensation and benefits | | | 439 | | | 441 | | | 880 | | | 950 | Consulting | | | 47 | | | 43 | | | 80 | | | 66 | Total research and development | | | 3,478 | | | 2,320 | | | 5,579 | | | 4,647 | General and administrative | | | | | | | | | | | | | Legal and professional fees | | | 985 | | | 1,074 | | | 1,910 | | | 1,907 | Consulting | | | 204 | | | 230 | | | 451 | | | 333 | Employee compensation and benefits | | | 471 | | | 444 | | | 997 | | | 951 | Other G&A (2) | | | 247 | | | 233 | | | 473 | | | 349 | Total general and administrative | | | 1,907 | | | 1,981 | | | 3,831 | | | 3,540 | Total operating expenses | | | 5,385 | | | 4,301 | | | 9,410 | | | 8,187 | Loss from operations | | | (5,385) | | | (4,301) | | | (9,410) | | | (8,187) | Total other income | | | 69 | | | 306 | | | 271 | | | 521 | Loss before income taxes | | $ | (5,316) | | $ | (3,995) | | $ | (9,139) | | $ | (7,666) |
(1)Other R&D expenses include clinical, non-clinical and preclinical services and other R&D expenditures that are not attributable to a single product candidate. (2)Other G&A expenses include insurance, software license fees, non-income state taxes, lease rental expenses and other G&A expenditures.
|